COVID-19'un Hastalık Modifiye Edici Tedavi Alan Multipl Sklerozlu Bireylerdeki Hastalık Aktivitesi, Progresyonu ve Bilişsel İşlev Bozukluğu Üzerine Etkisi

Apostolos-Pereira, S. L., et al. (2021). Clinical features of COVID-19 on patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm, 8, 1060. doi: https://doi.org/10.1212/NXI.0000000000001060

Arrambide, G., et al. (2021). SARS-CoV-2 infection in multiple sclerosis: Results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflamm, 8(5), e1024. doi: https://doi.org/10.1212/NXI.0000000000001024

Barzegar, M., et al. (2020). COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm, 7, 753. doi: https://doi.org/10.1212/NXI.0000000000000753

Barzegar, M., et al. (2021). Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Mult Scler Relat Disord, 52, 102947. doi: https://doi.org/10.1016/j.msard.2021.102947

Chyzhyk, V., et al. (2021). Is SARS-CoV-2 important for multiple sclerosis? Eur J Neurol, 2021, 492. doi: https://doi.org/10.1111/ene.14874

Conway, S., et al. (2021). COVID-19 and neurologic outcomes in multiple sclerosis and related disorders. Multiple Scler J, 2021, 765. doi: https://doi.org/10.1177/13524585211024128

Corrêa, D. G., et al. (2021). COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies. Mult Scler J, 27, 973–976. doi: https://doi.org/10.1177/1352458520949988

Czarnowska, A., et al. (2021). Symptoms after COVID-19 infection in individuals with multiple sclerosis in Poland. J Clin Med, 10, 225225. doi: https://doi.org/10.3390/jcm10225225

Das, D., et al. (2022). Neuromyelitis optica spectrum disorder post-COVID-19 infection. Indian J Ophthalmol, 70, 1833–1836. doi: https://doi.org/10.4103/ijo.IJO_61_22

Desforges, M., et al. (2019). Human coronaviruses and other respiratory viruses. Viruses, 12, 14. doi: https://doi.org/10.3390/v12010014

Dhillon, P. S., et al. (2021). Neurological disorders associated with COVID-19 hospital admissions. Front Neurol, 12, 640017. doi: https://doi.org/10.3389/fneur.2021.640017

Domingues, R. B., et al. (2020). First case of SARS-CoV-2 sequencing in CSF of a patient with suspected demyelinating disease. J Neurol, 267, 3154–3156. doi: https://doi.org/10.1007/s00415-020-09996-w

Etemadifar, M., et al. (2021). COVID-19 and the risk of relapse in multiple sclerosis patients. Mult Scler Relat Disord, 51, 102915. doi: https://doi.org/10.1016/j.msard.2021.102915

Etemadifar, M., et al. (2022). Does COVID-19 increase the long-term RRMS clinical activity? BMC Neurol, 22, 64. doi: https://doi.org/10.1186/s12883-022-02590-9

Fragoso, Y. D., et al. (2021). COVID-19 in a temporal relation to the onset of multiple sclerosis. Mult Scler Relat Disord, 50, 102863. doi: https://doi.org/10.1016/j.msard.2021.102863

Gutiérrez-Ortiz, C., et al. (2020). Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology, 95, e601–e605. doi: https://doi.org/10.1212/WNL.0000000000009619

Huang, C., et al. (2020). Clinical features of patients infected with coronavirus in Wuhan. Lancet, 395, 497–506. doi: https://doi.org/10.1016/S0140-6736(20)30183-5

Ide, T., et al. (2022). SARS-CoV-2-related MOGAD. Intern Med, 2022, 21. doi: https://doi.org/10.2169/internalmedicine.8709-21

Jentzer, A., et al. (2022). Neuromyelitis optica spectrum disorder following COVID-19 infection. J Neurol, 269, 2850–2853. doi: https://doi.org/10.1007/s00415-022-10972-9

Jossy, A., et al. (2022). COVID-19-associated optic neuritis. Indian J Ophthalmol, 70, 310–316. doi: https://doi.org/10.4103/ijo.IJO_2235_21

Karsidag, S., et al. (2021). Demyelinating disease of CNS concurrent with COVID-19. Cureus, 13, e17297. doi: https://doi.org/10.7759/cureus.17297

Khedr, E. M., et al. (2021). Acute neurological manifestations among Egyptian COVID-19 patients. Neuroepidemiology, 55, 109–118. doi: https://doi.org/10.1159/000513647

Khurana, D., et al. (2021). COVID-19 in multiple sclerosis: Experience from North India. J Neurol Sci, 429, 118164. doi: https://doi.org/10.1016/j.jns.2021.118164

Kogure, C., et al. (2021). MOG-associated optic neuritis in COVID-19. Medicine, 100, e25865. doi: https://doi.org/10.1097/MD.0000000000025865

Louapre, C., et al. (2020). Clinical characteristics and outcomes in MS patients with COVID-19. JAMA Neurol, 77(9), 1079–1088. doi: https://doi.org/10.1001/jamaneurol.2020.2681

Luetic, G., et al. (2021). COVID-19 in Argentine teriflunomide-treated MS patients. Mult Scler Relat Disord, 53, 103049. doi: https://doi.org/10.1016/j.msard.2021.103049

Maghzi, A. H., et al. (2020). COVID-19 in teriflunomide-treated MS patients. J Neurol, 267, 2790–2796. doi: https://doi.org/10.1007/s00415-020-09944-8

Mantero, V., et al. (2021). COVID-19 in dimethyl fumarate-treated MS patients. J Neurol, 268, 2023–2025. doi: https://doi.org/10.1007/s00415-020-10015-1

Marrodan, M., et al. (2019). The role of infections in multiple sclerosis. Mult Scler, 25, 891–901. doi: https://doi.org/10.1177/1352458518823940

Michelena, G., et al. (2022). Can COVID-19 exacerbate MS symptoms? Mult Scler Relat Disord, 57, 103368. doi: https://doi.org/10.1016/j.msard.2021.103368

Moore, L., et al. (2021). First presentation of multiple sclerosis with concurrent COVID-19 infection. eNeurologicalSci, 22, 100299. doi: https://doi.org/10.1016/j.ensci.2020.100299

Moreno-Torres, I., et al. (2021). Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol, 28(11), 3712–3721. doi: https://doi.org/10.1111/ene.15089

Moriguchi, T., et al. (2020). First case of meningitis/encephalitis associated with SARS-CoV-2. Int J Infect Dis, 94, 55–58. doi: https://doi.org/10.1016/j.ijid.2020.03.062

Möhn, N., et al. (2020). Mild COVID-19 despite teriflunomide and high-dose methylprednisolone. J Neurol, 267, 2803–2805. doi: https://doi.org/10.1007/s00415-020-09921-1

Naser Moghadasi, A., et al. (2021). The prevalence of COVID-19 infection in MS: A systematic review and meta-analysis. Neurol Sci, 42(8), 3093–3099. doi: https://doi.org/10.1007/s10072-021-05373-1

Oikonen, M., et al. (2011). Temporal relationship between viral infections and MS relapse. Mult Scler, 17, 672–680. doi: https://doi.org/10.1177/1352458510394397

Palao, M., et al. (2020). Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord, 45, 102377. doi: https://doi.org/10.1016/j.msard.2020.102377

Paterson, R. W., et al. (2020). Emerging spectrum of COVID-19 neurology. Brain, 143, 3104–3120. doi: https://doi.org/10.1093/brain/awaa240

Paybast, S., et al. (2022). One-year follow-up of MS patients during COVID-19 pandemic. Mult Scler Relat Disord, 60, 103712. doi: https://doi.org/10.1016/j.msard.2022.103712

Peters, J., et al. (2021). MOG-associated encephalitis following SARS-CoV-2. Mult Scler Relat Disord, 50, 102857. doi: https://doi.org/10.1016/j.msard.2021.102857

Pignolo, A., et al. (2021). Clinical onset and MS relapse after SARS-CoV-2 infection. Neurol Int, 13, 695–700. doi: https://doi.org/10.3390/neurolint13040066

Pinto, A. A., et al. (2020). CNS inflammatory vasculopathy with anti-MOG antibodies in COVID-19. Neurol Neuroimmunol Neuroinflamm, 7, 813. doi: https://doi.org/10.1212/NXI.0000000000000813

Qin, C., et al. (2020). Dysregulation of immune response in COVID-19. Clin Infect Dis, 71, 762–768. doi: https://doi.org/10.1093/cid/ciaa248

Ramagopalan, S. V., et al. (2009). Association of infectious mononucleosis with MS. Neuroepidemiology, 32, 257–262. doi: https://doi.org/10.1159/000201564

Reder, A. T., et al. (2021). COVID-19 in MS: Associations with DMTs. CNS Drugs, 35, 317–330. doi: https://doi.org/10.1007/s40263-021-00804-1

Salter, A., et al. (2021). Outcomes and risk factors associated with COVID-19 in MS. JAMA Neurol, 78(6), 699–708. doi: https://doi.org/10.1001/jamaneurol.2021.0687

Sandoval, F., et al. (2021). Neurologic features associated with SARS-CoV-2 in children. J Child Neurol, 36, 853–866. doi: https://doi.org/10.1177/0883073821989164

Simpson-Yap, S., et al. (2021). Associations of DMTs with COVID-19 severity. Neurology, 97, e1870–e1885. doi: https://doi.org/10.1212/WNL.0000000000012753

Sormani, M. P., et al. (2021). DMTs and COVID-19 severity in MS. Ann Neurol, 89, 780–789. doi: https://doi.org/10.1002/ana.26028

Thompson, A. J., et al. (2018). Diagnosis of multiple sclerosis: 2017 McDonald criteria. Lancet Neurol, 17, 162–173. doi: https://doi.org/10.1016/S1474-4422(17)30470-2

Verstrepen, K., et al. (2020). Neurological manifestations of COVID-19, SARS and MERS. Acta Neurol Belg, 120, 1051–1060. doi: https://doi.org/10.1007/s13760-020-01412-4

Vraka, K., et al. (2021). Encephalopathy in two pediatric patients with COVID-19. Case Rep Neurol Med, 2021, 6658000. doi: https://doi.org/10.1155/2021/6658000

Wildemann, B., et al. (2022). Severe MS exacerbation with Takotsubo cardiomyopathy during COVID-19. J Neurol, 269, 1138–1141. doi: https://doi.org/10.1007/s00415-021-10779-0

Winkelmann, A., et al. (2016). DMTs and infectious risks in MS. Nat Rev Neurol, 12(4), 217–233. doi: https://doi.org/10.1038/nrneurol.2016.36

Yavari, F., et al. (2020). Demyelinating changes alike to MS: Rare COVID-19 case. Case Rep Neurol Med, 2020, 6682251. doi: https://doi.org/10.1155/2020/6682251

Zhou, S., et al. (2020). Anti-MOG associated optic neuritis and myelitis in COVID-19. J Neuroophthalmol, 40, 398–402. doi: https://doi.org/10.1097/WNO.0000000000001049